Studying Nicotinamide Riboside to Improve Sleep and Memory in Older Adults Aged 65 to 85

What this Trial Is About

Poor sleep quality and short sleep duration are linked to cognitive impairment in older adults, often involving a decrease in brain-derived neurotrophic factor BDNF. This research evaluates the effects of nicotinamide riboside NR, a vitamin B3 form that increases NAD levels, on sleep and cognitive function in older adults. The study also explores how NR impacts serum BDNF, which may serve as a biomarker related to sleep quality. Participants will be randomly assigned to receive either 500 mg of NR twice daily or a placebo containing micro cellulose powder twice daily. The study lasts 12 weeks, during which the effects of NR supplementation on sleep quality and cognitive function will be assessed. Researchers will compare changes from the baseline to the endpoint in both sleep and cognition measures. Throughout the study, participants will undergo comprehensive sleep and cognitive evaluations using subjective and objective tools. Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, while cognitive function changes will also be measured. The study includes continuous monitoring of serum BDNF levels to examine its association with sleep improvements. Overall participation lasts 12 weeks with follow-up assessments at the end of this period.

Benefits of Nicotinamide Riboside Upon Cognition and Sleep